Method Article

Primary Human Nasal Epithelial Cells: Biobanking in the Context of Precision Medicine

DOI:

10.3791/63409

⸱

April 22nd, 2022

 ,  ,  ,  ,  ,  , 
1Institut Necker Enfants Malades, 2Université de Paris, 3Centre de Référence Maladies Rares Mucoviscidose et Maladies apparentées, Assistance Publique Hôpitaux de Paris

In This Article

Summary

$$\rightleftharpoonup{xx}$$ $$\longleftharp{xx}$$, $$\longrightharp{xx}$$,

Here we describe the isolation, amplification, and differentiation of primary human nasal epithelial (HNE) cells at the air-liquid interface and a biobanking protocol allowing to successfully freeze and then thaw amplified HNE. The protocol analyzes electrophysiological properties of differentiated HNE cells and CFTR-related chloride secretion correction upon different modulator treatments.

Abstract

$$\rightleftharpoonup{xx}$$ $$\longleftharp{xx}$$, $$\longrightharp{xx}$$,

Human nasal epithelial (HNE) cells are easy to collect by simple, non-invasive nasal brushing. Patient-derived primary HNE cells can be amplified and differentiated into a pseudo-stratified epithelium in air-liquid interface conditions to quantify cyclic AMP-mediated Chloride (Cl-) transport as an index of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) function. If critical steps such as quality of nasal brushing and cell density upon cryopreservation are performed efficiently, HNE cells can be successfully biobanked. Moreover, short-circuit current studies demonstrate that freeze-thawing does not significantly modify HNE cells' electrophysiological properties and response to CFTR modulators. In the culture conditions used in this study, when less than 2 x 106 cells are frozen per cryovial, the failure rate is very high. We recommend freezing at least 3 x 106 cells per cryovial. We show that dual therapies combining a CFTR corrector with a CFTR potentiator have a comparable correction efficacy for CFTR activity in F508del-homozygous HNE cells. Triple therapy VX-445 + VX-661 + VX-770 significantly increased correction of CFTR activity compared to dual therapy VX-809 + VX-770. The measure of CFTR activity in HNE cells is a promising pre-clinical biomarker useful to guide CFTR modulator therapy.

Introduction

$$\rightleftharpoonup{xx}$$ $$\longleftharp{xx}$$, $$\longrightharp{xx}$$,

Cystic Fibrosis (CF) is an autosomal recessive disorder resulting from mutations in the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) gene leading to the absence or dysfunction of the CFTR protein, an anion channel located at the apical surface of epithelia1,2. Recent advances in CFTR therapy have improved the prognosis of the disease, and the last approved drugs combining CFTR correctors and CFTR potentiators led to major improvements in lung function and quality of life for CF patients carrying the most frequent mutation p.Phe508del mutation (F508del)3,4. Despite this promising therapeutic progress, around 10% of CF patients are ineligible as they carry mutations that are unrescuable by these CFTR modulators. For these patients, there is a need to test other drugs or drug combinations to find the most efficient combination for specific mutations, highlighting the importance of personalized therapies.

Human nasal epithelial (HNE) cells are easy to collect by simple, non-invasive nasal brushing and allow quantification of cyclic AMP-mediated Chloride (Cl−) transport as an index of CFTR function. HNE cells yield an accurate model of human airway, but their lifespan is limited in culture. Thanks to the optimization of culture techniques, patient-derived primary HNE cells can be conditionally reprogrammed with Rho-associated kinase inhibitor (ROCKi), amplified, and differentiated into a pseudo-stratified epithelium in air-liquid interface (ALI) conditions on microporous filters5,6. Numerous culture protocols for HNE culture exist (commercially available, serum-free, "homemade", co-culture with feeder-cells, etc.), and choice of media and culture conditions have been described to impact growth, cell population differentiation and epithelial function7,8. The protocol here presents a simplified, feeder-free, ROCKi amplification method that allows to successfully obtain a large number of HNE cells that are then differentiated at ALI for CFTR function assays.

We have demonstrated that, in differentiated HNE cells, a 48 h treatment with CFTR modulators is sufficient to induce electrophysiological correction of CFTR dependent Cl- current and that the correction observed in vitro may be correlated with the patient's clinical improvement9. HNE cells, therefore, represent an appropriate model not only for fundamental CF research but for pre-clinical studies with patient-specific CFTR modulator testing. In this context of personalized therapy, the goal of the protocol was to validate that cryopreserved HNE cells from CF patients, grown in our conditions, were an appropriate model for CFTR correction studies, and similar results could be expected when comparing CFTR dependent Cl- transport from fresh and frozen-thawed cells. The study also assessed different CFTR modulators' efficacy when using dual and triple therapies.

Access restricted. Please log in or start a trial to view this content.

Protocol

$$\rightleftharpoonup{xx}$$ $$\longleftharp{xx}$$, $$\longrightharp{xx}$$,

All experiments were performed following the guidelines and regulations described by the Declaration of Helsinki and the Huriet-Serusclat law on human research ethics.

1. Preparation of flasks and different media

  1. Prepare amplification, air-liquid, and freezing medium as described in Table 1.
  2. Prepare a stock solution of human collagen IV by dissolving 50 mg of collagen in 100 mL of 0.2% glacial acetic acid. Mix on a magnetic stirrer for at least 1 h, and filter sterilize the solution. Store at 4 °C for up to 6 months in a glass bottle, protected from light.
  3. Prepare a working solution of collagen IV by diluting the stock solution 1:5 in double-distilled water. Store at 4 °C for up to 6 months.
  4. Coat plastic cell culture flasks or transwell filters with the collagen working solution. Evenly distribute 100 µL for 0.33 cm2 transwell filters, 500 µL for 25 cm2 flasks, and 1 mL for 75 cm2 flasks on the whole growth surface of the flask.
    NOTE: This can be achieved by gently inclining the flask from side to side. Alternatively, to facilitate coating the flasks, an increased volume can be used, and when the entire surface is evenly covered, collagen solution is aspirated to leave only the indicated volume. The aspirated collagen solution can then be used immediately to coat the next flask (i.e., for three 75 cm2 flasks, distribute 3 mL of collagen solution evenly in the first flask, aspirate 2 mL, which are then used for the next flask, and so on).
  5. Leave the cell culture flasks in the incubator for a minimum of 2 h or overnight. Aspirate the collagen thoroughly and leave the flasks to dry in the incubator or under the hood for a minimum of 20 min or overnight.
  6. Wash with 10 mL of Mg2+- and Ca2+-free DPBS, allow to dry in the incubator, and store in aluminum foil to protect from light. Store the flasks for up to 6 months at room temperature (RT).

2. Nasal brushing

NOTE: Ensure that nasal brushing is performed while the participant does not have an acute infection. If CF patients present a pulmonary infection, refer to the patient's antibiogram and add additional antibiotics to the amplification medium. Human nasal epithelial cells were collected by nasal brushing from F508del/F508del patients as previously described9.

  1. Ask the patient to blow their nose, then topically anesthetize the mucosa of both nostrils using cotton meshes soaked in xylocaine 5% with naphazoline solution.
  2. Gently brush the medial wall and the inferior turbinate of both nostrils using a cytology brush. Soak the brush in a 15 mL tube with 2 mL of commercially available flushing medium; shake gently to detach cells. Repeat brushing in the second nostril.
  3. Add the following antibiotics to the flushing medium: Penicillin (100 U/mL), Streptomycin (100 µg/mL), Tazocillin (10 µg/mL), Amphotericin B (2.5 µg/mL) and Colimycin (16 µg/mL).
    ​NOTE: Nasal brushings can be shipped at RT to dedicated labs for expansion and culture and can be seeded up to 72 h after brushing.

3. Isolation of HNE

NOTE: HNE were isolated from the cytology brush, washed with Mg2+- and Ca2+-free DPBS, dissociated with 0.25% Trypsin, and seeded onto a 25 cm2 plastic flask as previously described10.

  1. Detach cells from the cytology brush by repeatedly passing the brush through a 1000 µL pipette cone and rinsing with 2 mL of Mg2+- and Ca2+-free DPBS. Centrifuge at 500 x g for 5 min at 4 °C and discard the supernatant.
  2. Resuspend the pellet in 0.25% Trypsin for 8-12 min to dissociate cells. Stop the enzymatic reaction by adding 5 mL of the amplification medium.
  3. Centrifuge at 500 x g for 5 min at 4 °C and discard the supernatant. Resuspend the pellet in 8 mL of the amplification medium and seed onto a 25 cm2 collagen-coated flask. Grow at 37 °C and 5% CO2. This corresponds to passage 0.
  4. The following day, replace the medium with 5 mL of fresh amplification medium and monitor the cells daily for attachment, morphology (cells should have a cohesive cobblestone appearance), and number.
    ​NOTE: The initial seeding density varies depending on the quality of the nasal brushing and the proportion of epithelial cells. Freshly isolated HNE cells usually reach 80%-90% confluency within 3-10 days. A slower growth rate is suggestive of insufficient epithelial cells in the sample and should be discarded.

4. Amplification and passaging of human nasal epithelial cells

  1. Grow human nasal epithelial cells in the amplification medium at 37 °C and 5% CO2 on collagen-coated flasks until 80%-90% confluency, changing medium every 48-72 h. For 25 cm2 flasks, use 5 mL of amplification medium and 10 mL for 75 cm2 flasks.
  2. When cells reach 80%-90% confluency, wash the cells with 10 mL of Mg2+- and Ca2+-free DPBS, aspirate, and discard.
  3. Add 1 mL of 0.25% Trypsin for a 25 cm2 flask (or 2 mL of Trypsin for a 75 cm2 flask) and return to the incubator (37 °C, 5% CO2) for 8-12 min.
  4. Tap the flask firmly, with the palm of the hand, to help the cells detach.
  5. Add 10 mL of the amplification medium to stop the enzymatic reaction. Vigorously rinse the flask, using the 10 mL pipette to draw up and expel the amplification medium over the flask surface to rinse and detach cells.
  6. Centrifuge at 500 x g for 5 min at 4 °C and discard the supernatant.
  7. Resuspend the pellet in 5-10 mL of the amplification medium.
  8. Count the cells using a hemocytometer.
    ​NOTE: Cells can be frozen at this point (see steps 5.1-5.3). If further amplification is required, re-seed onto collagen-coated flasks (a 25 cm2 flask can be expanded into three 75 cm2 flasks, a greater dilution is not recommended).

5. Cryopreservation of primary nasal epithelial cells

NOTE: Grow HNE cells until passage 1 before biobanking to obtain enough cells to facilitate cell growth when thawed. Biobanking is, however, possible at initial passage 0 or passage 2. The following cryopreservation steps are adapted to all passages.

  1. After cell counting, centrifuge at 500 x g for 5 min at 4 °C, and discard the supernatant
  2. Resuspend the pellet in the enriched freezing medium (Table 1) to obtain 3 x 106-5 x 106 cells per mL and per cryovial.
  3. Slowly freeze the cells by reducing the temperature at ~1 °C per min in an appropriate cryo-freezing container at -80 °C. The next day, move the preserved sample to a nitrogen storage container for long-term storage (the present study is limited to 17 months storage).

6. Thawing frozen amplified HNE cells

  1. Warm up the water bath to 37 °C. Prepare the amplification medium as described in Table 1 and warm the medium to 37 °C.
  2. Remove cryovials from the nitrogen storage tank and rapidly place them in the water bath, taking care not to submerge the whole vial in the water. Remove the cryovials from the water bath when only a small frozen droplet remains. Wipe the vial with 70% alcohol, wipe dry, and place under the hood.
  3. Using a 1 mL pipette, transfer the thawed cells to an empty 15 mL tube.
  4. In a drop-wise manner, add 1 mL of warm amplification medium. After 1 min, add another 1 mL of amplification medium and wait an additional minute.
  5. Add 10 mL of the amplification medium and centrifuge for 2 min at 500 x g.
  6. Aspirate and discard the supernatant. Resuspend the cell pellet in a volume of amplification medium required to achieve a cell density of at least 1 x 106 cells/mL.
  7. Seed the cells onto a collagen-coated flask containing the amplification medium.
    1. If the cryovial contains more than 4 x 106 cells, seed onto a 75 cm2 flask, in 10 mL of the amplification medium
    2. If cryovial contains less than 4 x 106 cells, seed cells onto a 25 cm2 flask, in 5 mL of the amplification medium
  8. Incubate at 37 °C, 5% CO2, and visually observe cell expansion over the next 2-3 days.
  9. Then, perform cell amplification as detailed in section 4.
    ​NOTE: If few cells were harvested in step 4.7. (i.e., if freezing at passage 0 before expansion), steps 6.5. and 6.6. can be omitted, and cells can be seeded directly onto a 25 cm2 collagen-coated flask without centrifugation. The medium must then be changed the following day to remove dimethyl sulfoxide (DMSO).

7. Differentiation of human nasal epithelial cells at the air-liquid interface

NOTE: HNE were differentiated at the air-liquid interface as previously described10.

  1. Seed the cells at a density of 330,000 cells/filter on 0.33 cm2 collagen-coated porous filters and supplement with 300 µL of the amplification medium at the apical side and 900 µL of the air-liquid medium at the basolateral side.
  2. After 3 days, aspirate the apical medium and culture the cells at the air-liquid interface for 3-4 weeks in the air-liquid medium to establish a differentiated epithelium. Change the basal medium every 48-72 h.

8. CFTR modulators

  1. Prepare air-liquid medium containing CFTR modulators. Use VX-445, VX-661, and VX-809 at a final concentration of 3 µM and VX-770 at 100 nM. Use corrector ABBV-2222 at 1 µM final concentration and potentiator ABBV-974 at 10 µM. Use 100% DMSO to dissolve all CFTR modulators.
  2. Prepare air-liquid medium containing the same amount of 100% DMSO as in corrector medium.
  3. Add the medium containing drugs or DMSO to the basolateral side of polarized HNE cells grown at an air-liquid interface and incubate for 24 h in 5% CO2 at 37 °C.
  4. After 24 h, aspirate and discard the medium and replace with fresh medium prepared as in steps 8.1-8.2., and further incubate for a 24 h period in 5% CO2 at 37 °C.

9. Ussing chamber studies

  1. Measure short-circuit current measurements (Isc) under voltage-clamp conditions as previously described9.
    NOTE: Transepithelial electrical resistance (TEER) of cultures was measured with a chopstick voltmeter, and only cultures reaching at least 200 Ω·cm2 were considered for the following experiments. Filters of polarized HNE cells were mounted in Ussing chambers, and short-circuit current measurements (Isc) were measured under voltage-clamp conditions.

10. Immunocytochemistry

  1. Perform Immuno-detection as previously described9.
    ​NOTE: CFTR immuno-detection was performed using the anti-CFTR C-terminal (24-1) monoclonal antibody overnight at a 1/100 dilution. Zona-occludens-1 (ZO-1) (1/500 dilution), alpha-tubulin (1/300 dilution), Muc 5AC (1/250 dilution) and cytokeratin 8 (1/250 dilution) staining were done on additional filters. After washing with PBS-Triton-X100 0.1%, goat secondary antibodies conjugated to Alexa 488 or 594 were added for 30 min in 10% goat serum (1/1000 dilution). After a final wash, filters were cut from support and mounted with Vectashield mounting medium containing DAPI. A confocal microscope (63x/1.4 oil differential interference contrast λ blue PL APO objective) was used to capture images, which were analyzed with the ImageJ software.

11. Statistical analysis

  1. Perform statistical analysis using appropriate software.
    NOTE: Statistical analysis was performed using S.A.S software. As several HNE filters were obtained per patient and per condition, quantitative parameters were expressed as median values (± SEM) per patient. Comparisons (mean ± SD) were carried out using Wilcoxon matched pairs signed rank test or unpaired t-test.

Access restricted. Please log in or start a trial to view this content.

Results

$$\rightleftharpoonup{xx}$$ $$\longleftharp{xx}$$, $$\longrightharp{xx}$$,

Fresh HNE cells cultured at the air-liquid interface display typical features of the polarized and differentiated respiratory epithelium as assessed by immunostaining (Figure 1). HNE cells re-differentiate into a heterogeneous layer of epithelial cells (positive keratin 8 immunostaining) that mimic the in vivo situation of a pseudo-stratified respiratory epithelium composed of ciliated (positive alpha-tubulin staining) and non-ciliated mucus-producing goblet cells (positive Muc5Ac i...

Access restricted. Please log in or start a trial to view this content.

Discussion

$$\rightleftharpoonup{xx}$$ $$\longleftharp{xx}$$, $$\longrightharp{xx}$$,

The use of patient-derived nasal epithelial cells as surrogates for human bronchial epithelial (HBE) cells to measure CFTR activity in the context of personalized medicine has been proposed as HNE reproduce cells' properties in culture9,11. The strong advantage of HNE over HBE cell cultures is that they are easily and non-invasively sampled. Short-circuit current measurements in HNE cell cultures enable assessment of CFTR-dependent Cl- transport ac...

Access restricted. Please log in or start a trial to view this content.

Disclosures

$$\rightleftharpoonup{xx}$$ $$\longleftharp{xx}$$, $$\longrightharp{xx}$$,

The authors report no competing financial interests related to this publication or scientific video production.

Acknowledgements

$$\rightleftharpoonup{xx}$$ $$\longleftharp{xx}$$, $$\longrightharp{xx}$$,

We warmly thank all patients and their families for participation in the study. This work was supported by grants from French Association Vaincre la Mucoviscidose; French Association ABCF 2 and Vertex Pharmaceuticals Innovation Awards.

Access restricted. Please log in or start a trial to view this content.

Materials

List of materials used in this article
NameCompanyCatalog NumberComments
ABBV-2222SelleckchemS8535
ABBV-974SelleckchemS8698
Advanced DMEM/F-12Life Technologies12634010
Alexa 488 goat secondary antibodyInvitrogenA11001
Alexa 594 goat secondary antibodyInvitrogenA11012
Amphotericin BLife Technologies15290026
Anti-alpha-tubulin antibodyAbcamab80779
Anti-CFTR monoclonal antibody (24-1)R&D SystemsMAB25031
Anti-cytokeratin 8 antibodyProgen61038
Anti-Muc5AC antibodySanta Cruz Biotechsc-20118
Anti-ZO-1 antibodySanta Cruz Biotechsc-10804
Ciprofloxacinprovided by Necker Hospital Pharmacy
ColimycinSanofiprovided by Necker Hospital Pharmacy
Collagen type IVSigma-Aldrich MerckC-7521
cytology brushLaboratory GYNEAS02.104
DMSOSigma-Aldrich MerckD2650
EGFLife TechnologiesPHG0311
EpinephrinSigma-Aldrich MerckE4375
F12-Nutrient MixtureLife Technologies11765054
FBSLife Technologies10270106
FerticultFertipro NVFLUSH020
Flasks 25Thermo Scientific156.367
Flasks 75Thermo Scientific156.499
Glacial acetic acidVWR20104.298
HEPESSigma-Aldrich MerckH3375
HydrocortisoneSigma-Aldrich MerckSLCJ0893
InsulinSigma-Aldrich MerckI0516
Mg2+ and Ca2+-free DPBSLife Technologies14190094
Penicillin/StreptomycinLife Technologies15140130
TazocillinMylanprovided by Necker Hospital Pharmacy
Transwell FiltersSigma-Aldrich MerckCLS3470-48EA
Triton-X100Sigma-Aldrich MerckT8787
Trypsin 0,25%Life Technologies25200056
Vectashield mounting medium with DAPIVector LaboratoriesH-1200
VX-445SelleckchemS8851
VX-661SelleckchemS7059
VX-770SelleckchemS1144
VX-809SelleckchemS1565
Xylocaine naphazoline 5%Aspen Franceprovided by Necker Hospital Pharmacy
Y-27632SelleckchemS1049

References

$$\rightleftharpoonup{xx}$$ $$\longleftharp{xx}$$, $$\longrightharp{xx}$$,
  1. Kim, S. J., Skach, W. R. Mechanisms of CFTR folding at the endoplasmic reticulum. Frontiers in Pharmacology. 3, 201(2012).
  2. Lukacs, G. L., Verkman, A. S. CFTR: folding, misfolding and correcting the ΔF508 conformational defect. Trends in Molecular Medicine. 18 (2), 81-91 (2012).
  3. Wainwright, C. E., et al. Lumacaftor-Ivacaftor in patients with cystic fibrosis homozygous for Phe508del CFTR. The New England Journal of Medicine. 373 (3), 220-231 (2015).
  4. Griese, M., et al. Safety and efficacy of elexacaftor/tezacaftor/ivacaftor for 24 weeks or longer in people with cystic fibrosis and one or more F508del alleles: Interim results of an open-label phase 3 clinical trial. American Journal of Respiratory and Critical Care Medicine. 203 (3), 381-385 (2021).
  5. Horani, A., Nath, A., Wasserman, M. G., Huang, T., Brody, S. L. Rho-associated protein kinase inhibition enhances airway epithelial basal-cell proliferation and lentivirus transduction. American Journal of Respiratory Cell and Molecular Biology. 49 (3), 341-347 (2013).
  6. Liu, X., et al. Conditional reprogramming and long-term expansion of normal and tumor cells from human biospecimens. Nature Protocols. 12 (2), 439-451 (2017).
  7. Saint-Criq, V., et al. Choice of differentiation media significantly impacts cell lineage and response to CFTR modulators in fully differentiated primary cultures of cystic fibrosis human airway epithelial cells. Cells. 9 (9), 2137(2020).
  8. Bukowy-Bieryłło, Z. Long-term differentiating primary human airway epithelial cell cultures: how far are we. Cell Communication and Signaling: CCS. 19 (1), 1-18 (2021).
  9. Pranke, I. M., et al. Correction of CFTR function in nasal epithelial cells from cystic fibrosis patients predicts improvement of respiratory function by CFTR modulators. Scientific Reports. 7 (1), 7375(2017).
  10. Noel, S., et al. Correlating genotype with phenotype using CFTR-mediated whole-cell Cl− currents in human nasal epithelial cells. The Journal of Physiology. , (2021).
  11. Brewington, J. J., et al. Brushed nasal epithelial cells are a surrogate for bronchial epithelial CFTR studies. JCI Insight. 3 (13), 99385(2018).
  12. Pranke, I., et al. Might brushed nasal cells be a surrogate for cftr modulator clinical response. American Journal of Respiratory and Critical Care Medicine. 199 (1), 123-126 (2019).
  13. de Courcey, F., et al. Development of primary human nasal epithelial cell cultures for the study of cystic fibrosis pathophysiology. American Journal of Physiology-Cell Physiology. 303 (11), 1173-1179 (2012).
  14. Devalia, J. L., Sapsford, R. J., Wells, C. W., Richman, P., Davies, R. J. Culture and comparison of human bronchial and nasal epithelial cells in vitro. Respiratory Medicine. 84 (4), 303-312 (1990).
  15. McDougall, C. M., et al. Nasal epithelial cells as surrogates for bronchial epithelial cells in airway inflammation studies. American Journal of Respiratory Cell and Molecular Biology. 39 (5), 560-568 (2008).
  16. Mosler, K., et al. Feasibility of nasal epithelial brushing for the study of airway epithelial functions in CF infants. Journal of Cystic Fibrosis: Official Journal of the European Cystic Fibrosis Society. 7 (1), 44-53 (2008).
  17. Tosoni, K., Cassidy, D., Kerr, B., Land, S. C., Mehta, A. Using drugs to probe the variability of trans-epithelial airway resistance. PLOS One. 11 (2), 0149550(2016).
  18. Schögler, A., et al. Characterization of pediatric cystic fibrosis airway epithelial cell cultures at the air-liquid interface obtained by non-invasive nasal cytology brush sampling. Respiratory Research. 18 (1), 215(2017).
  19. Müller, L., Brighton, L. E., Carson, J. L., Fischer, W. A., Jaspers, I. Culturing of human nasal epithelial cells at the air liquid interface. Journal of Visualized Experiments: JoVE. (80), e50646(2013).
  20. Awatade, N. T., et al. Measurements of functional responses in human primary lung cells as a basis for personalized therapy for cystic fibrosis. EBioMedicine. 2 (2), 147-153 (2014).
  21. Brewington, J. J., et al. Generation of human nasal epithelial cell spheroids for individualized cystic fibrosis transmembrane conductance regulator study. Journal of Visualized Experiments: JoVE. (134), e57492(2018).
  22. Wiszniewski, L., et al. Long-term cultures of polarized airway epithelial cells from patients with cystic fibrosis. American Journal of Respiratory Cell and Molecular Biology. 34 (1), 39-48 (2006).
  23. Reynolds, S. D., et al. Airway progenitor clone formation is enhanced by Y-27632-dependent changes in the transcriptome. American Journal of Respiratory Cell and Molecular Biology. 55 (3), 323-336 (2016).
  24. Suprynowicz, F. A., et al. Conditionally reprogrammed cells represent a stem-like state of adult epithelial cells. Proceedings of the National Academy of Sciences of the United States of America. 109 (49), 20035-20040 (2012).
  25. Awatade, N. T., et al. Significant functional differences in differentiated Conditionally Reprogrammed (CRC)- and Feeder-free Dual SMAD inhibited-expanded human nasal epithelial cells. Journal of Cystic Fibrosis. 20 (2), 364-371 (2021).
  26. Veit, G., et al. Allosteric folding correction of F508del and rare CFTR mutants by elexacaftor-tezacaftor-ivacaftor (Trikafta) combination. JCI Insight. 5 (18), 139983(2020).
  27. Dale, T. P., Borg D'anastasi, E., Haris, M., Forsyth, N. R. Rock Inhibitor Y-27632 enables feeder-free, unlimited expansion of Sus scrofa domesticus swine airway stem cells to facilitate respiratory research. Stem Cells International. 2019, 1-15 (2019).
  28. Laselva, O., et al. Rescue of multiple class II CFTR mutations by elexacaftor+tezacaftor+ivacaftor mediated in part by the dual activities of elexacaftor as both corrector and potentiator. The European Respiratory Journal. 57 (6), 2002774(2021).
  29. Li, X., Krawetz, R., Liu, S., Meng, G., Rancourt, D. E. ROCK inhibitor improves survival of cryopreserved serum/feeder-free single human embryonic stem cells. Human Reproduction. 24 (3), 580-589 (2008).
  30. Neuberger, T., Burton, B., Clark, H., Van Goor, F. Use of primary cultures of human bronchial epithelial cells isolated from cystic fibrosis patients for the pre-clinical testing of CFTR modulators. Methods in Molecular Biology. 741, Clifton, N.J. 39-54 (2011).
  31. Laselva, O., et al. Emerging pre-clinical modulators developed for F508del-CFTR have the potential to be effective for ORKAMBI resistant processing mutants. Journal of Cystic Fibrosis. 20 (1), 106-119 (2021).

Access restricted. Please log in or start a trial to view this content.

Reprints and Permissions

Request permission to reuse the text or figures of this JoVE article

Request Permission

Tags

Primary HNE CellsNasal BrushingAir Liquid InterfaceCFTR ActivityCystic Fibrosis TherapyCell CryopreservationShort Circuit CurrentCFTR ModulatorsPersonalized Medicine

Related Articles